Here’s something we don’t see that often — authors retracting one of their articles because it included new data.
But that is the case with a 2017 review exploring the potential genetic and hormonal underpinnings of gender identity. The authors Rosa Fernández García and Eduardo Pásaro Mendez told Retraction Watch that they asked bioethics journal Cuadernos de Bioética to withdraw their review after realizing it “indirectly” mentioned some of their unpublished work. According to García, the authors had hoped to publish the new data in a scientific paper before the review came out, but the review ended up being published first.
When researchers submitted a paper about a type of microparticle to PNAS, they wanted to give credit where it was due, and cite an unpublished manuscript that helped guide their work. But the journal’s policy forbid citing unpublished work, and the reference was removed before publication. Now, concerns from the authors of that unpublished work have prompted the journal to have a change of heart.
Originally published June 17, 2016, the paper was retracted Jan. 15. Led by corresponding author Xavier Altafaj, of the University of Barcelona (UB) and Bellvitge Biomedical Research Institute (IDIBELL), researchers described using an amino acid, D-serine, to treat a child with a rare genetic disorder that affects neurons.
According to the notice, the researchers did use D-serine in lab work used as proof-of-concept; however, when it came time to try it in the patient, as a result of a “communication error:”
Here’s a rather odd case: A postdoctoral researcher says his former boss changed his name on a paper without his permission. According to the postdoc, Antonio Herrera-Merchan, his principal investigator at University of Granada insisted on the name change to distance them both from a scandal in Herrera-Merchan’s previous lab.
After publishing a paper in Oncotarget in October 2017, Herrera-Merchan’s name was changed on the paper. Now, two versions of the paper exist: an earlier version that lists Antonio Herrera-Merchan as first author, and the current version that spells his name without “Merchan.”*
We’ve obtained an email exchange between his former boss, Pedro Medina, and Oncotarget, requesting the name change.
What Caught Our Attention: A big peer review (and perhaps academic mentorship) fail. These researchers used the wrong anticoagulant for their blood samples, leading them to believe that certain blood components were fighting microbes. The authors counted the number of colonies to show how well or poorly Tuberculin mycobacteria were growing in cultures — but blood samples need anticoagulants to prevent clots before analysis, and they used an anticoagulant that actually prevented the microbes from colonizing. The authors (and reviewers) should have known this from Continue reading Caught Our Notice: Dear peer reviewer, please read the methods section. Sincerely, everyone
A once-prominent stem cell biologist, who recently lost both her job and a sizable grant, has lost her fifth paper.
Recently, Molecular and Cellular Biology retracted a 2003 paper by Susana Gonzalez. Last February, the National Center for Cardiovascular Research (CNIC) in Spain dismissed her from her position over allegations of misconduct. The reason: suspicions of data manipulation.
As with a previous retraction, the journal said Gonzalez “could not be reached for approval of this retraction.”
A journal has issued expression of concerns (EOCs) for four papers after a concerned reader notified the editors of issues in several figures.
According to the EOCs, the Journal of Cell Science (JCS) discussed the concerns with the corresponding author, José Ignacio Rodriguez-Crespo, and subsequently notified his institution, Complutense University of Madrid. Last year, all four papers were questioned on PubPeer (1,2,3,4).
In 2014, researchers condemned the Spanish Government for “destroying the R&D horizon of Spain and the future of a complete generation” in the acknowledgment section of a paper about wireless networks.